Randomized, Double-blind, Crossover, Placebo-controlled, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure

Trial Profile

Randomized, Double-blind, Crossover, Placebo-controlled, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs MYK 491 (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Adverse reactions
  • Sponsors MyoKardia
  • Most Recent Events

    • 16 Feb 2018 New trial record
    • 14 Feb 2018 According to a MyoKardia media release, first patient has been dosed in this study and topline results are anticipated in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top